Global Congenital Heart Disease Market Hits $4.8 Billion in 2025 with 8.2% CAGR

Published: Feb 2026

The congenital heart disease market was valued at $4.8 billion in 2025 and is projected to reach $10.5 billion by 2035, growing at a CAGR of 8.2% during the forecast Period (2026-2035). The growth of the global congenital heart disease (CHD) market is driven by increasing demand from hospitals, specialty cardiac centers, and pediatric healthcare providers for advanced diagnostic, surgical, and interventional treatment solutions. Congenital heart disease encompasses a range of structural abnormalities of the heart present at birth, requiring early diagnosis, long-term clinical management, and, in many cases, surgical or catheter-based interventions. Market demand is primarily concentrated in pediatric cardiology and neonatal care settings, where timely detection and specialized treatment are critical to improving survival rates and long-term patient outcomes.

Browse the full report description of “Congenital Heart Disease Market Size, Share & Trends Analysis By Defect Type (Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects) By Diagnosis (Echocardiogram, Chest X-ray, MRI, and Others), By Treatment (Medications, Implantable Heart Device, Catheter Procedure, Open Heart Surgery, and Heart Transplant), End-Users (Hospitals and Clinics, Diagnostic Centers, Others), Forecast Period (2026-2035)” of https://www.omrglobal.com/industry-reports/congenital-heart-disease-market

Market development is influenced by rising birth prevalence of congenital heart defects, improved survival of pediatric patients into adulthood, and advancements in cardiac imaging, minimally invasive procedures, and medical devices. According to global health organizations, congenital heart disease is among the most common birth defects worldwide, contributing significantly to infant morbidity and mortality. Increased awareness, expanded newborn screening programs, and the availability of advanced echocardiography, cardiac MRI, and genetic testing have supported earlier diagnosis and intervention. Additionally, continuous innovation in implantable devices, surgical techniques, and post-operative care has improved quality of life for both pediatric and adult CHD patients.

Regulatory frameworks and healthcare policies play a significant role in shaping the global congenital heart disease market, particularly in relation to device approval, surgical standards, and reimbursement for specialized cardiac care. In the United States, congenital heart disease treatments and devices are regulated by the Food and Drug Administration (FDA), while reimbursement support is provided through public and private healthcare programs for pediatric and adult congenital cardiology services. In Europe, CHD-related interventions follow established clinical guidelines and medical device regulations under regional healthcare systems. In the Asia-Pacific region, increasing investments in pediatric cardiac care infrastructure, expanding access to specialized treatment centers, and government initiatives aimed at improving maternal and child health have contributed to market growth. As healthcare systems continue to prioritize early diagnosis, specialized treatment, and long-term disease management, the congenital heart disease market is expected to maintain steady expansion globally.

Key Innovators Driving Congenital Heart Disease Treatment Advancements

The key players in the global congenital heart disease market include Abbott Laboratories, Boston Scientific Corp., Edwards Lifesciences Corp., Medtronic plc, Terumo Corp., among others. These companies focus on the development and commercialization of medical devices and interventional solutions used in the diagnosis and treatment of congenital heart defects, including septal defects, valve abnormalities, and complex structural heart conditions. Their product portfolios include transcatheter heart valves, occlusion devices, stents, guidewires, and minimally invasive cardiac intervention systems that support pediatric and adult congenital cardiology procedures across hospital and specialty cardiac care settings.

  • In December 2025, Abbott Laboratories received FDA clearance and CE Mark approval for its Amplatzer Piccolo Delivery System for the treatment of patients with congenital heart disease. The Amplatzer Piccolo Delivery System is designed to support minimally invasive transcatheter closure of patent ductus arteriosus (PDA) in premature and low-birth-weight infants, enabling precise device placement in small and fragile cardiac anatomy. This regulatory approval strengthens Abbott’s position in pediatric structural heart interventions and expands its portfolio of catheter-based solutions for the management of congenital heart defects.
  • In January 2025, Medtronic plc received CE Mark approval for its Harmony Transcatheter Pulmonary Valve (TPV) System for the treatment of patients with congenital heart disease. The Harmony TPV System is designed to enable minimally invasive pulmonary valve replacement in patients with native or surgically repaired right ventricular outflow tracts, reducing the need for open-heart surgery and supporting improved recovery outcomes. This regulatory milestone expands Medtronic’s transcatheter therapy portfolio for congenital heart disease and strengthens its position in minimally invasive structural heart interventions.

Market Coverage

  • The market number available for – 2025-2035
  • Base year- 2025
  • Forecast period- 2026-2035
  • Segment Covered-
    • by Diagnosis 
    • by Diagnostic Modality
    • by Treatment
    • by End-User
  • Regions Covered-
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World
  • Competitive Landscape - Abbott Laboratories, Boston Scientific Corp., Edwards Lifesciences Corp., Medtronic plc, Terumo Corp., among others. 

Key questions addressed by the report.

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?

Congenital Heart Disease Market Report Segment

By Diagnosis 

  • Heart Valve Defects
  • Heart Wall Defects
  • Blood Vessel Defects

By Diagnostic Modality

  • Echocardiogram
  • Chest X-Ray
  • MRI Scan
  • Others

By Treatment

  • Medications
  • Implantable Heart Treatments
  • Catheter Procedures
  • Open Heart Surgery
  • Heart Transplant

By End-User

  • Hospitals and Clinics
  • Diagnostic Centres
  • Others

Congenital Heart Disease Market Report Segment by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia and New Zealand
  • ASEAN Economies
  • Rest of Asia-Pacific

Rest of the World

  • Latin America
  • Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/congenital-heart-disease-market